Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) kicked off on Monday, down -3.20% from the previous trading day, before settling in for the closing price of $14.07. Over the past 52 weeks, CNTA has traded in a range of $8.46-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -210.04% over the last five years. While this was happening, its average annual earnings per share was recorded 38.48%. With a float of $84.74 million, this company’s outstanding shares have now reached $133.55 million.
The firm has a total of 77 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.36%, operating margin of -1304.95%, and the pretax margin is -1470.43%.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 36.55%, while institutional ownership is 57.62%. The most recent insider transaction that took place on Jun 25 ’25, was worth 138,642. In this transaction Chief Business Officer of this company sold 10,000 shares at a rate of $13.86, taking the stock ownership to the 122,279 shares. Before that another transaction happened on Jun 24 ’25, when Company’s General Counsel sold 12,000 for $14.02, making the entire transaction worth $168,218. This insider now owns 105,386 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.99% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Take a look at Centessa Pharmaceuticals plc ADR’s (CNTA) current performance indicators. Last quarter, stock had a quick ratio of 14.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 120.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Analysing the last 5-days average volume posted by the [Centessa Pharmaceuticals plc ADR, CNTA], we can find that recorded value of 0.83 million was lower than the volume posted last year of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 78.97%.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 44.92%, which indicates a significant decrease from 70.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.71% in the past 14 days, which was lower than the 62.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.92, while its 200-day Moving Average is $15.20. Now, the first resistance to watch is $14.10. This is followed by the second major resistance level at $14.57. The third major resistance level sits at $15.01. If the price goes on to break the first support level at $13.18, it is likely to go to the next support level at $12.74. Now, if the price goes above the second support level, the third support stands at $12.27.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
The company with the Market Capitalisation of 1.82 billion has total of 133,555K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -235,760 K annual income. Company’s last quarter sales were recorded 15,000 K and last quarter income was -26,140 K.
